Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics.

Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.